Bamco Inc. NY increased its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 8.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 226,300 shares of the specialty pharmaceutical company’s stock after acquiring an additional 16,800 shares during the period. Bamco Inc. NY’s holdings in Flexion Therapeutics were worth $5,667,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nicholas Investment Partners LP boosted its holdings in Flexion Therapeutics by 104.6% in the 4th quarter. Nicholas Investment Partners LP now owns 74,562 shares of the specialty pharmaceutical company’s stock valued at $1,867,000 after purchasing an additional 38,128 shares in the last quarter. Gagnon Securities LLC boosted its holdings in Flexion Therapeutics by 134.6% in the 4th quarter. Gagnon Securities LLC now owns 338,607 shares of the specialty pharmaceutical company’s stock valued at $8,479,000 after purchasing an additional 194,276 shares in the last quarter. Gagnon Advisors LLC boosted its holdings in Flexion Therapeutics by 77.4% in the 4th quarter. Gagnon Advisors LLC now owns 192,438 shares of the specialty pharmaceutical company’s stock valued at $4,819,000 after purchasing an additional 83,940 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Flexion Therapeutics by 35.2% in the 4th quarter. Geode Capital Management LLC now owns 303,958 shares of the specialty pharmaceutical company’s stock valued at $7,611,000 after purchasing an additional 79,115 shares in the last quarter. Finally, Brant Point Investment Management LLC purchased a new stake in Flexion Therapeutics in the 4th quarter valued at approximately $2,626,000. 94.71% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have weighed in on FLXN. BidaskClub lowered Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday. Finally, Berenberg Bank began coverage on Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $99.00.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.27). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $1.29 million. research analysts expect that Flexion Therapeutics Inc will post -4.13 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3254676/bamco-inc-ny-grows-position-in-flexion-therapeutics-inc-flxn.html.
Flexion Therapeutics Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.